Literature DB >> 16806893

Mammalian cell factories for efficient and stable protein expression.

Louise M Barnes1, Alan J Dickson.   

Abstract

As the commercial market for therapeutic protein production from mammalian cells has expanded, so has the requirement for improved efficiency and stability of production. Rapid developments have been made in understanding the molecular environment of transgenes in chromatin, including elucidation of the contribution of epigenetic modifications to expression, and this understanding is being used to enhance expression from host cells. Technical advances surrounding the 'omics' revolution are enabling the rational identification of complex control factors that define the flow of information from transgene to desired protein. Using information from 'omics' interrogations, directed cell engineering has been employed to enhance the translational and secretory capacity of host cells. Taken together, these recent advances are likely to lead to improved routes for protein production in the future.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16806893     DOI: 10.1016/j.copbio.2006.06.005

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  14 in total

1.  Improved antibody production in Chinese hamster ovary cells by ATF4 overexpression.

Authors:  Ahmad M Haredy; Akitoshi Nishizawa; Kohsuke Honda; Tomoshi Ohya; Hisao Ohtake; Takeshi Omasa
Journal:  Cytotechnology       Date:  2013-09-13       Impact factor: 2.058

2.  Using cell engineering and omic tools for the improvement of cell culture processes.

Authors:  Darrin Kuystermans; Britta Krampe; Halina Swiderek; Mohamed Al-Rubeai
Journal:  Cytotechnology       Date:  2007-02-24       Impact factor: 2.058

Review 3.  A review of the mammalian unfolded protein response.

Authors:  Anirikh Chakrabarti; Aaron W Chen; Jeffrey D Varner
Journal:  Biotechnol Bioeng       Date:  2011-08-09       Impact factor: 4.530

4.  In vivo crystallization of human IgG in the endoplasmic reticulum of engineered Chinese hamster ovary (CHO) cells.

Authors:  Haruki Hasegawa; John Wendling; Feng He; Egor Trilisky; Riki Stevenson; Heather Franey; Francis Kinderman; Gary Li; Deirdre Murphy Piedmonte; Timothy Osslund; Min Shen; Randal R Ketchem
Journal:  J Biol Chem       Date:  2011-04-04       Impact factor: 5.157

5.  The impact of intragenic CpG content on gene expression.

Authors:  Asli Petra Bauer; Doris Leikam; Simone Krinner; Frank Notka; Christine Ludwig; Gernot Längst; Ralf Wagner
Journal:  Nucleic Acids Res       Date:  2010-03-04       Impact factor: 16.971

6.  Towards the molecular characterization of the stable producer phenotype of recombinant antibody-producing NS0 myeloma cells.

Authors:  Y Prieto; L Rojas; L Hinojosa; I González; D Aguiar; K de la Luz; A Castillo; R Pérez
Journal:  Cytotechnology       Date:  2011-03-20       Impact factor: 2.058

7.  Identifying bottlenecks in transient and stable production of recombinant monoclonal-antibody sequence variants in Chinese hamster ovary cells.

Authors:  Megan Mason; Bernadette Sweeney; Katharine Cain; Paul Stephens; Susan T Sharfstein
Journal:  Biotechnol Prog       Date:  2012-05-21

Review 8.  Nucleoside, nucleotide and oligonucleotide based amphiphiles: a successful marriage of nucleic acids with lipids.

Authors:  Arnaud Gissot; Michel Camplo; Mark W Grinstaff; Philippe Barthélémy
Journal:  Org Biomol Chem       Date:  2008-03-05       Impact factor: 3.876

9.  Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression.

Authors:  Susan E Witko; J Erik Johnson; Narender K Kalyan; Barbara K Felber; George N Pavlakis; Maninder K Sidhu; R Michael Hendry; Stephen A Udem; Christopher L Parks
Journal:  J Virol Methods       Date:  2009-11-24       Impact factor: 2.014

Review 10.  Post-translational modifications of recombinant proteins: significance for biopharmaceuticals.

Authors:  Nigel Jenkins; Lisa Murphy; Ray Tyther
Journal:  Mol Biotechnol       Date:  2008-06       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.